Imad Khreim
Psychiatry · Palmer, MANPI 1104842731
Payments from drug & device makers
Across 278 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$890
- Lundbeck LLC$852
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$524
- Takeda Pharmaceuticals U.S.A., Inc.$492
- Neurocrine Biosciences, Inc.$471
- Otsuka America Pharmaceutical, Inc.$467
- plus $2K from 11 others
What the payments were for
- Food & beverage$5,05797%
- Education$1433%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $890 |
| Lundbeck LLC | 43 | $852 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $524 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $492 |
| Neurocrine Biosciences, Inc. | 24 | $471 |
| Otsuka America Pharmaceutical, Inc. | 21 | $467 |
| Sunovion Pharmaceuticals Inc. | 26 | $435 |
| Teva Pharmaceuticals USA, Inc. | 17 | $430 |
| Corium, LLC | 13 | $176 |
| Alkermes, Inc. | 8 | $172 |
| Eisai Inc. | 3 | $63 |
| Shire North American Group Inc | 3 | $61 |
| Johnson & Johnson | 4 | $54 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Neos Therapeutics, LP | 2 | $35 |
| Pernix Therapeutics Holdings, Inc. | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
How this compares
$5,200 in reported general payments places this provider in the 90th percentile of 1,431 psychiatry providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 12 | $24,001 |
| TrintellixVortioxetine Hydrobromide | 26 | $12,128 |
| Adderall XrDextroamphetamine/Amphetamine | 13 | $5,292 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 64 | $2,995 |
| Clonazepam | 398 | $2,139 |
| Sertraline Hcl | 167 | $1,957 |
| Vilazodone Hcl | 13 | $1,504 |
| Ziprasidone Hcl | 36 | $1,414 |
| Lamotrigine | 116 | $1,326 |
| Fluvoxamine Maleate | 37 | $1,297 |
| Duloxetine Hcl | 67 | $1,252 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 50 | $1,178 |
| Quetiapine Fumarate | 92 | $1,158 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 47 | $1,062 |
| Bupropion XlBupropion Hcl | 51 | $1,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $54 | $24,00112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $492 | $12,12826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,431 psychiatry providers in Massachusetts.
Other psychiatry in Palmer
- Lee CohenBoston$7M
- Dyanna DomiliciBoston$5.8M
- Arkadiy StolyarBelmont$3.3M
- Maurizio FavaBoston$2.8M
- Marc ShayAmesbury$1.7M
- Martha StarkNewton$1.6M
- Hadine JoffeBoston$1.5M
- Malini NairWinchester$1M
- Xiaoduo FanWorcester$950K
- Anthony RothschildWorcester$838K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.